Table 2 Population data used for development and evaluation of the captopril PBPK model in healthy adults.
Sr. no | Population | No. of subjects | Dose (mg) | Portion of females | Age (year) | Weight (kg) | References |
|---|---|---|---|---|---|---|---|
| Â | iv Bolus | ||||||
1 | Healthy | 5 | 10 | 0 | 24–34 | 68.1–88.7 | |
2 | Healthy | 7 | 2.78 | 0 | 20–33 | – | |
7 | 5.67 | 0 | 20–33 | – | |||
7 | 11.4 | 0 | 20–33 | – | |||
| Â | Oral healthy | ||||||
3 | Healthy | 24 | 25 | 0.167 | 19–25 | 45–86 | |
4 | Healthy | 5 | 10 | 0 | 24–34 | 68.1–88.7 | |
5 | Healthy | 12 | 25 | – | 20–24 | – | |
12 | 50 | – | 20–24 | – | |||
6 | Healthy | 12 (Male) | 100 | 0 | 21.88–25.78 | 67.53–76.85 | |
12 (Female) | 100 | 1 | 19.55–25.61 | 51.47–60 | |||
7 | Healthy | 10 | 100 | 0 | 18–35 | 64.2–85 | |
8 | Healthy | 12 | 100 | 0 | 18–33 | 60–106 | |
9 | Healthy | 12 | 100 | 0 | 65–76 | 63–89 | |
